Comparison of the efficacy of candesartan and losartan: A meta-analysis of trials in the treatment of hypertension

Journal of Human Hypertension

Volumn 24, Issue 8, 2010, Pages 525-531

  Meredith, P A ^a   Murray, L S ^a   McInnes, G T ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

angiotensin II type 1 receptor blockers; anti hypertensive treatment; benzimidazoles; candesartan; losartan; randomized controlled trials

Indexed keywords

CANDESARTAN; CANDESARTAN PLUS HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; LOSARTAN; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

ARTICLE; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; HYPERTENSION; LOW DRUG DOSE; META ANALYSIS; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; COMPARATIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; HUMANS; HYPERTENSION; LOSARTAN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TETRAZOLES;

EID: 77954814946     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2009.99     Document Type: Article

References (32)

1. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA et al. Blood pressure, stroke, and coronary heart disease: part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838.
2. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. Br Med J 2008; 336: 1121-1123.
3. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43: 10.
4. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. Management of Arterial Hypertension of the European Society of Hypertension. European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25(6): 1105-1108.
5. Conlin PR, Spence JD, Williams B, Ribeiro AB, Saito I, Benedict C et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000; 13: 418-426.
6. Elmfeldt D, Olofsson B, Meredith P. The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy. Blood Press 2002; 11: 293-301.
7. Goa KL, Wagstaff AJ. Losartan potassium: a review of its pharmacology, clinical efficacy, and tolerability in the management of hypertension. Drugs 1996; 51(5): 820-845.
8. Easthope SE, Jarvis B. Candesartan cilexetil: an update of its use in essential hypertension. Drugs 2002; 62(8): 1253-1287.
9. Vauquelin G, Fierens F, Van Liefde I. Long-lasting angiotensin type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans. JHypertens 2006; 24(1): S23-S30.
10. Belz GG, Fuchs B, Malerczyk C, Magin SG, Roll S, Mutschler E. Inhibition of angiotensin II pressor response and ex vivo angiotensin II radioligand binding by candesartan cilexetil and losartan in healthy human volunteers. J Hum Hypertens 1997; vfll(Suppl 2): S45-S47.
11. Review Manager (RevMan). [Computer program]. Version 5.0 The Nordic Cochrane Centre, The Cochrane Collaboration: Copenhagen, 2008.
12. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
13. Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press 1998; 7: 53-59.
14. Baguet J-P, Nisse-Durgeat S, Mouret S, Asmar R, Mallion J-M. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring. Int J Clin Pract 2006; 60: 391-398.
15. Bakris G, Gradman A, Reif M, Wofford M, Munger M, Harris S et al. Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study. J Clin Hypertens 2001; 3: 16-21.
16. Gradman AH, Lewin A, Bowling BT, Tonkon M, Deedwania PC, Kezer AE et al. Comparative effects of candesartan cilexetil and losartan in patients with systemic hypertension. Candesartan Versus Losartan Efficacy Comparison (CANDLE) Study Group. Heart Dis 1999; 1: 52-57.
17. Koenig W. Comparison of the efficacy and tolerability of combination tablets containing candesartan cilexetil and hydrochlorothiazide or losartan and hydrochlor-othiazide in patients with moderate to severe hypertension. Results of the CARLOS-Study. Clin Drug Investig 2000; 19: 239-246.
18. Koh KK, Han SH, Chung WJ, Ahn JY, Jin DK, Kim HS et al. Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension. Am J Cardiol 2004; 93: 1432-1435.
19. Lacourciere Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators. Am J Hy- pertens 1999; 12: 1181-1187.
20. Manolis AJ, Grossman E, Jelakovic B, Jacovides A, Bernhardi DC, Cabrera WJ et al. Effects of losartan and candesartan monotherapy and losartan/hydrochlor-othiazide combination therapy in patients with mild to moderate hypertension Losartan Trial Investigators. Clin Ther 2000; 22: 1186-1203.
21. Matsuda H, Hayashi K, Homma K, Yoshioka K, Kanda T, Takamatsu I et al. Differing anti-proteinuric action of candesartan and losartan in chronic renal disease. Hypertens Res Clin Exp 2003; 26: 875-880.
22. Nishimura T, Hashimoto J, Ohkubo T, Kikuya M, Metoki H, Asayama K et al. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements. Clin Exp Hypertens 2005; 27: 477-489.
23. Ohman KP, Milon H, Valnes K. Efficacy and toler-ability of a combination tablet of candesartan cilexetil and hydrochlorothiazide in insufficiently controlled primary hypertension-comparison with a combination of losartan and hydrochlorothiazide. Blood Press 2000; 9: 214-220.
24. Rayner BL, Trinder YA, Baines D, Isaacs S, Opie LH. Effect of losartan versus candesartan on uric acid, renal function, and fibrinogen in patients with hypertension and hyperuricemia associated with diuretics. Am J Hypertens 2006; 19: 208-213.
25. Vidt DG, White WB, Ridley E, Rahman M, Harris S, Vendetti J et al. A forced titration study of antihyper-tensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II. J Hum Hypertens 2001; 15: 475-480.
26. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913.
27. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemio-logical studies. Br Med J 2009; 338: b1665.
28. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11 000 participants from 42 trials. Am JMed 2009; 122: 290-300.
29. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention For End-point reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003. (Pubitemid 34286536)
30. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B et al. The Study On Cognition And Prognosis In The Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875-886. (Pubitemid 36677151)
31. Meredith PA, Murray LS, McMurray JJV. A putative placebo comparison of the SCOPE and LIFE trials. J Renin Angiotensin Aldosterone Syst 2004; 5(2): 59-63.
32. Kjeldsen SE, Stalhammar J, Hasvold P, Bodegard J, Olsson U, Russell D et al. Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. J Hum Hypertens 2010; 24: 263-273.